UBS Group
NAMSW icon

UBS Group’s NewAmsterdam Pharma Warrant NAMSW Stock Holding History

UBS Group’s Portfolio NAMSW Stock Details NAMSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.94K Hold
396
– – ﹤0.01% 8538
2025
Q4 		$9.27K Sell
396
-116
-23% -$2.88K ﹤0.01% 8301
2025
Q3 		$8.76K Sell
512
-481
-48% -$6.19K ﹤0.01% 8641
2025
Q2 		$7.94K Sell
993
-1,388
-58% -$11.6K ﹤0.01% 8986
2025
Q1 		$21.4K Sell
2,381
-100
-4% -$1.09K ﹤0.01% 8189
2024
Q4 		$35.4K Buy
+2,481
New +$26.8K ﹤0.01% 7511
2023
Q4 		– Sell
-38
Closed -$72 – 9699
2023
Q3 		$72 Buy
+38
New +$74 ﹤0.01% 8945
2023
Q1 		– Sell
-1,076
Closed -$936 – 10086
2022
Q4 		$936 Buy
+1,076
New +$886 ﹤0.01% 10025

Other funds holding NAMSW

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return
VI
Vestcor Inc Fredericton, New Brunswick, Canada $3.63B AUM 21.49% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

UBS Group's NAMSW Position: Q1 2026 in Review

UBS Group held its NewAmsterdam Pharma Warrant (NAMSW) position steady in Q1 2026 at 396 shares worth $7.94K. The position accounts for ﹤0.01% of the portfolio, ranked #8538.

UBS Group first reported a position in NAMSW in Q4 2022 and has held it in 8 quarters since. The position peaked at $35.4K in Q4 2024. 9 funds tracked by Wall St. Rank hold NAMSW as of Q1 2026.

  • UBS Group held 396 shares of NewAmsterdam Pharma Warrant worth $7.94K as of Q1 2026.
  • UBS Group left its NewAmsterdam Pharma Warrant share count unchanged in Q1 2026.
  • NewAmsterdam Pharma Warrant made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #8538 holding.
  • UBS Group first reported a position in NewAmsterdam Pharma Warrant in Q4 2022 and has held it in 8 quarters since.
  • UBS Group's NewAmsterdam Pharma Warrant position peaked at $35.4K in Q4 2024.
  • 9 funds tracked by Wall St. Rank held NewAmsterdam Pharma Warrant as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.